NCT04023669View on ClinicalTrials.gov

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 8, 2019

Primary Completion Date

May 1, 2023

Study Completion Date

January 13, 2025

Conditions
Brain TumorBrain Tumor, RecurrentBrain Tumor, RefractoryBrain Tumor, PediatricMedulloblastomaMedulloblastoma RecurrentMedulloblastoma, Non-WNT/Non-SHHMedulloblastoma, Non-WNT/Non-SHH, Group 3Medulloblastoma, Non-WNT/Non-SHH, Group 4Brain CancerCNS CancerCNS TumorCNS Neoplasm
Interventions
DRUG

Prexasertib

IV

DRUG

Cyclophosphamide

IV

DRUG

Gemcitabine

IV

BIOLOGICAL

filgrastim

Given subcutaneously (SQ). Alternatively, pegfilgrastim may be given.

BIOLOGICAL

peg-filgrastim

Given subcutaneously (SQ). Alternatively, filgrastim may be given.

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

St. Jude Children's Research Hospital

OTHER

NCT04023669 - Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | Biotech Hunter | Biotech Hunter